Swedish Orphan Biovitrum
SOBI | ST
Overview
Corporate Details
- ISIN(s):
- SE0000872095 (+51 more)
- LEI:
- 549300124Y3MQI87PT35
- Country:
- Sweden
- Address:
- Tomtebodavagen 23A, 112 76 Stockholm
- Website:
- https://www.sobi.com/en
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
At Sobi, we are transforming life for people with rare diseases. As an international biopharmaceutical company, we provide access to innovative treatments in the areas of haematology, immunology and specialty care. - Two therapeutic areas – Haematology and Immunology – and a portfolio of products within Specialty Care - Our extended half-life factor replacement treatments are the most prescribed treatments for haemophilia - A and B respectively in several markets - A strong portfolio of on-market products, and an extensive portfolio of pre-market assets - An international biopharmaceutical company covering the entire value chain - We put our focus where we can have the greatest impact, in late-stage research and development, and in patient access and commercialisation
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-28 00:55 |
Regulatory News Service
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and…
|
English | 227.3 KB | |
| 2025-06-28 00:55 |
Regulatory News Service
FDA godkänner Gamifant® (emapalumab-lzsg) som den första behandlingen för vuxna…
|
Swedish | 244.4 KB | |
| 2025-05-08 11:30 |
Declaration of Voting Results & Voting Rights Announcements
Kommuniké från Sobis årsstämma
|
Swedish | 148.7 KB | |
| 2025-05-08 11:30 |
Declaration of Voting Results & Voting Rights Announcements
Bulletin from Sobi’s Annual General Meeting (AGM)
|
English | 158.7 KB | |
| 2025-04-29 08:00 |
Earnings Release
|
Swedish | 4.1 MB | |
| 2025-04-29 08:00 |
Earnings Release
|
English | 4.1 MB | |
| 2025-02-05 08:01 |
Earnings Release
|
Swedish | 4.1 MB | |
| 2025-02-05 08:01 |
Earnings Release
|
English | 4.0 MB | |
| 2025-01-10 18:00 |
Earnings Release
Sobis intäkter för helåret 2024 högre än tidigare uppskattningar
|
Swedish | 144.9 KB | |
| 2025-01-10 18:00 |
Earnings Release
Sobi's full year 2024 revenue higher than previous estimate
|
English | 156.9 KB | |
| 2024-12-11 09:30 |
Declaration of Voting Results & Voting Rights Announcements
Kommuniké från Sobis extra bolagsstämma
|
Swedish | 131.8 KB | |
| 2024-12-11 09:30 |
Declaration of Voting Results & Voting Rights Announcements
Bulletin from Sobi’s Extraordinary General Meeting (EGM)
|
English | 129.2 KB | |
| 2024-10-24 08:01 |
Earnings Release
|
Swedish | 4.1 MB | |
| 2024-10-24 08:01 |
Earnings Release
|
English | 4.1 MB | |
| 2024-08-29 14:45 |
Declaration of Voting Results & Voting Rights Announcements
Sobi har genomfört emissioner av C-aktier
|
Swedish | 150.2 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-30 | Katy Mazibuko | Other | Sell | 1,500 | 480,000.00 SEK |
| 2024-08-30 | Katy Mazibuko | Other | Sell | 269 | 86,012.75 SEK |
| 2024-08-12 | Sara Karlsson | Other | Buy | 86 | 23,391.79 SEK |
| 2024-07-25 | Mahmood Ladha | Other | Buy | 84,585 | 12,360,406.05 SEK |
| 2024-07-23 | Mahmood Ladha | Other | Sell | 84,585 | 24,614,235.00 SEK |
| 2024-06-10 | Christin Wesström | Other | Other | 7,433 | N/A |
| 2024-06-03 | Guido Oelkers | Other | Buy | 117,332 | 23,965,061.00 SEK |
| 2024-05-30 | Guido Oelkers | Other | Sell | 117,332 | 32,090,302.00 SEK |
| 2024-05-15 | Henrik Stenqvist | Other | Buy | 72,534 | 14,815,069.50 SEK |
| 2024-05-13 | Henrik Stenqvist | Other | Sell | 72,534 | 20,766,484.20 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
GenSight Biologics S.A. | France | SIGHT | |
|
Gentian Diagnostics ASA | Norway | GENT | |
|
Genus PLC | United Kingdom | GNS | |
|
Grace Breeding Ltd. | Israel | GRAC | |
|
Group 107 Ltd. | Israel | G107 | |
|
Guard Therapeutics International AB | Sweden | GUARD | |
|
Gubra A/S | Denmark | GUBRA | |
|
Hadasit Bio Holding Ltd. | Israel | HDST-M | |
|
Hansa Biopharma | Sweden | HNSA | |
|
HEMOGENYX PHARMACEUTICALS PLC | United Kingdom | HEMO |